Interestingly, BRAF fusions were observed in about 3% of melanomas, including some non-spitzoid melanomas; in these tumors, BRAF fusions are mutually exclusive of other mutations in the MAPK pathway and determine a constitutive BRAF kinase activity; the BRAF fusions are not sensitive to the inhibitory effects of vemurafenib, but are sensitive to MEK inhibitor [111]. This evidence concerns the gene BRAF and melanoma.